Related Experiment Video
Updated: May 23, 2026

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies
Published on: May 31, 2024
[ARCHITECT Chagas(®): a new diagnostic tool in Chagas disease]
M Asunción Iborra-Bendicho1, Miriam Albert-Hernández, Carmen Márquez-Contreras
1Servicio de Microbiología y Parasitología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, España. asunib@yahoo.com
Objective:
To evaluate a new chemiluminescent microparticle immunoassay (ARCHITECT Chagas(®), Abbott).
Methods:
In this study, 165 samples were tested by two different serological tests. The ARCHITECT Chagas(®) assay was performed using ARCHITECT i2000(SR) system (Abbott).
Results:
The sensitivity and specificity of ARCHITECT assay was 100% and 96.6%, respectively. The concordance rate was 0.96 (95%CI: 0.92-1) for ELISA and 0.91 (95%CI: 0.85-0.97) for immunofluorescence assay (IFA).
Conclusions:
The ARCHITECT Chagas(®) assay demonstrates a sensitivity and specificity similar to ELISA and IFA assays; it allows a large volume of samples to be processed with a good standardization and reproducibility, as well as an objective interpretation.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis II: Clinical Features and Diagnostic Tests
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Mitral Stenosis II: Clinical features and Diagnostic Tests

